In addition to apoptosis-inducing drugs, anti-inflammatory agents selective for cyclooxygenase 2 enzyme (COX-2) are traditionally reported be an effective adjuvant strategy for cancer therapy. This evidence concerns the gene PTGS2 and cancer.